The U.S. Food and Drug Administration has withdrawn its emergency use authorization for the antimalarial drug hydroxychloroquine, once seen by some — including President Trump — as a game-changing treatment for COVID-19 patients.
The decision, outlined in a 15-page document released Monday, addresses a small portion of the drug’s use. Specifically, it pulls back the availability of hydroxychloroquine sulfate, as well as chloroquine phosphate, from the Strategic National Stockpile for use among hospitalized COVID-19 patients.